<span style='font-size:46px; line-height:46px;'>89%</span>
<span style='font-size:24px; line-height:24px;'>The highest primary patency<br>in long lesions at 12 months (28.7 cm)
<span style='font-size:46px; line-height:46px;'>24%</span>
<span style='font-size:24px; line-height:24px;'>higher primary patency vs. PTA at 3 years in pivotal trial lesions<sup>5<sup>
GO THE DISTANCE
PRIOR TO DCB
Three-year results from the IN.PACT Global Study. Tepe G. CIRSE 2018. Long-term results of the IN.PACT SFA randomized Trial. Four-year outcomes: Schneider P. VIVA 2017.
IN.PACT™ Admiral™ IFU M052624T001 Rev 1H. Primary patency is defined as freedom from core laboratory-assessed restenosis (duplex ultrasound PSVR ≤ 2.4) or clinically driven target lesion revascularization through 12 months (adjudicated by a clinical events committee blinded to the assigned treatment). Patency per Kaplan-Meier estimates at 12 months (provisional stent rate of 42.5%).
Lutonix 035 DCB Instructions for Use BAW1387400r3 (2016).
Zeller T, Peeters P, Bosiers M, et al. Heparin-bonded stent-graft for the treatment of TASC II C and D femoropopliteal lesions: the Viabahn-25 cm trial. J Endovasc Ther. December 2014;21(6):765-774.
Medtronic Data on file. 3-year Outcomes: Schneider et al. Circ Cardiovasc Interv. 2018;11:e005891. Treatment of Drug-Coated Balloons IS Durable to 3 Years in the Femoropopliteal Arteries. PRIMARY PATENCY. Freedom from core laboratory-assessed restenosis (duplex ultrasound PSVR ≤ 2.4) and clinically driven target lesion revascularization through 12, 24, and 36 months (adjudicated by a Clinical Events Committee blinded to the assigned treatment). The primary patency was calculated based on Kaplan-Meier estimates.
Ansel G. Stented vs. Non-stented Outcomes at 2 Years: A Sub-analysis of the In.PACT Global Study. Presented at LINC 2018; Leipzig, Germany.
™* Third party brands are trademarks of their respective owners.